Document is current
Any future updates will be listed below
-
Authors
Skibba, Melissa
Ma, Zonghui
Wilson, Carole L.
Liu, Zhiqing
Chen, Haiying
Tian, Bing
Harr, Thomas J.
Schnapp, Lynn M
Sandbo, Nathan
Zhou, Jia
Brasier, Allan R.
-
Funding
Funding for this research was provided by:
Congressionally Directed Medical Research Programs (PR231315)
Falk Foundation (MSN256229)
National Center for Advancing Translational Sciences (UL1TR002373)
- License Information
-
More Information
Article History
Received: 30 January 2025
Accepted: 18 June 2025
First Online: 2 July 2025
Declarations
:
: All vertebrate animals experiments were conducted using a protocol reviewed and approved by the University of Wisconsin-Madison School of Medicine and Public Health Institutional Animal Care and Use Committee (IACUC), adhering to guidelines set by National Institutes of Health (NIH) and Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).
: Not applicable.
: JZ, BT and ARB hold patents on chemistry of BRD4 inhibitors. JZ and ARB are co-founders of Quadragenics Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
